INSM Insmed Inc

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at the following investor conferences taking place in New York City:

• The Cantor Fitzgerald Global Healthcare Conference, on Monday, September 25, 2017 at 8:00 a.m. ET.
• The Leerink Partners Rare Disease Roundtable, on Wednesday, September 27, 2017 at 9:00 a.m. ET.

The presentations will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcasts will be archived for a period of 90 days following the conclusion of each live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The Company’s lead product candidate is ALIS for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal.  Insmed has released top-line results from the phase 3 CONVERT study indicating the trial met the primary endpoint of culture conversion. The Company is not aware of any approved inhaled therapies specifically indicated for refractory NTM lung disease caused by MAC in North America, Japan or Europe.  Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Investor Contact:

Blaine Davis
Vice President, Head of Investor Relations
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com